🟢 Novo Nordisk is trading 3.1% up today on relief bounce after Wegovy earnings selloff

Novo Nordisk is trading 3.1% up at €40.36 as it rebounds from a sharp selloff following its Q2 earnings report.

• The stock faced pressure on August 5 after a narrow sales miss for the Wegovy pill and a trial setback for the obesity drug CagriSema overshadowed raised full-year guidance.
• Today's recovery reflects a relief bounce as investors reassess the recent selloff amid a broadly positive backdrop for the healthcare sector.